Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- VCEL +8.4%, ESEA +3.6%, JT +2.2%, INAP +1.2%
M&A news:
- XL +31.4% (AXA Group (AXAHY) confirms merger agreement at $57.60 per XL share)
Other news:
- CLSD +53.5% (announces positive topline results from its pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis)
- CVRS +19% (receives FDA clearance for first automated robotic movement in technIQ Series for CorPath GRX platform)
- ONTX +18.4% (presents new data for Rigosertib Combination with Azacitidine)
- ZYNE +8.7% (highlights results of a 'positive' meeting held with the FDA regarding its planned development strategy for ZYN002 in Fragile X syndrome), AIMT +5.7% (presents results from Pivotal Phase 3 PALISADE Trial of AR101)
- VNDA +4.5% (announces that HETLIOZ 'demonstrated significant and clinically meaningful benefits in nighttime and daytime symptoms of jet lag disorder'), FNSR+3% (to join S&P SmallCap 600)
- AZN +1.1% (receives EMA acceptance for regulatory submission for Forxiga), .
Analyst comments:
- IPI +8.1% (upgraded to Market Perform from Underperform at Cowen)
- EOLS +5.3% (initiated with a Overweight at Cantor Fitzgerald)
- VRX +4.5% (upgraded to Buy from Hold at Deutsche Bank)
- GRPN +1.6% (upgraded to Equal-Weight from Underweight at Morgan Stanley)